Intellia Therapeutics Receives $70,000,000 Series B Financing Round

  • Feed Type
  • Date
    9/1/2015
  • Company Name
    Intellia Therapeutics
  • Mailing Address
    130 Brookline Street Cambridge, MA 02139 USA
  • Company Description
    Intellia Therapeutic’s core mission is to lead the industry in therapeutic gene editing, utilizing the promise of the CRISPR/Cas9 technology. We are solely focused on the research and clinical development of gene editing therapies for patients with genetically-based diseases.
  • Website
    http://www.intelliatx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $70,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The company intends to use the proceeds to accelerate the development of its pipeline, expand its platforms for gene editing and delivery, as well as to continue to strengthen its leading intellectual property portfolio.
  • M&A Terms
  • Venture Investor
    OrbiMed
  • Venture Investor
    Fidelity Management & Research Company
  • Venture Investor
    Janus Capital
  • Venture Investor
    Foresite Capital
  • Venture Investor
    Sectoral Asset Management
  • Venture Investor
    EcoR1 Capital Management
  • Venture Investor
    Undisclosed